Medical Dialogues
  • Dermatology
Login Register
This site is intended for healthcare professionals only
Login Register
  • Medical Jobs
  • Medical Matrimony
  • MD Brand Connect
  • MDTV
    • Breaking News
    • Medical News Today
    • Health News Today
    • Latest
    • Journal Club
    • Medico Legal Update
    • Latest Webinars
    • MD Shorts
    • Health Dialogues
Medical Dialogues
  • Medical News & Guidelines
      • Anesthesiology
      • Cardiology and CTVS
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endocrinology
      • ENT
      • Gastroenterology
      • Medicine
      • Nephrology
      • Neurology
      • Obstretics-Gynaecology
      • Oncology
      • Ophthalmology
      • Orthopaedics
      • Pediatrics-Neonatology
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
      • Laboratory Medicine
      • Diet
      • Nursing
      • Paramedical
      • Physiotherapy
  • Health news
      • Doctor News
      • Government Policies
      • Hospital & Diagnostics
      • International Health News
      • MCI News
      • Medical Organization News
      • Medico Legal News
      • NBE News
      • NMC News
  • AYUSH
    • Ayurveda
    • Homeopathy
    • Siddha
    • Unani
    • Yoga
  • State News
      • Andaman and Nicobar Islands
      • Andhra Pradesh
      • Arunachal Pradesh
      • Assam
      • Bihar
      • Chandigarh
      • Chattisgarh
      • Dadra and Nagar Haveli
      • Daman and Diu
      • Delhi
      • Goa
      • Gujarat
      • Haryana
      • Himachal Pradesh
      • Jammu & Kashmir
      • Jharkhand
      • Karnataka
      • Kerala
      • Ladakh
      • Lakshadweep
      • Madhya Pradesh
      • Maharashtra
      • Manipur
      • Meghalaya
      • Mizoram
      • Nagaland
      • Odisha
      • Puducherry
      • Punjab
      • Rajasthan
      • Sikkim
      • Tamil Nadu
      • Telangana
      • Tripura
      • Uttar Pradesh
      • Uttrakhand
      • West Bengal
  • Medical Education
      • Ayush Education News
      • Dentistry Education News
      • Medical Admission News
      • Medical Colleges News
      • Medical Courses News
      • Medical Universities News
      • Nursing education News
      • Paramedical Education News
      • Study Aborad
  • Industry
      • Health Investment News
      • Health Startup News
      • Medical Devices News
      • Pharma News
      • Pharmacy Education News
      • Industry Perspective
  • MDTV
      • Health Dialogues MDTV
      • Health News today MDTV
      • Latest Videos MDTV
      • Latest Webinars MDTV
      • MD shorts MDTV
      • Medical News Today MDTV
      • Medico Legal Update MDTV
      • Top Videos MDTV
      • Health Perspectives MDTV
      • Journal Club MDTV
This site is intended for healthcare professionals only
LoginRegister
Medical Dialogues
LoginRegister
  • Home
  • Medical news & Guidelines
    • Anesthesiology
    • Cardiology and CTVS
    • Critical Care
    • Dentistry
    • Dermatology
    • Diabetes and Endocrinology
    • ENT
    • Gastroenterology
    • Medicine
    • Nephrology
    • Neurology
    • Obstretics-Gynaecology
    • Oncology
    • Ophthalmology
    • Orthopaedics
    • Pediatrics-Neonatology
    • Psychiatry
    • Pulmonology
    • Radiology
    • Surgery
    • Urology
    • Laboratory Medicine
    • Diet
    • Nursing
    • Paramedical
    • Physiotherapy
  • Health news
    • Doctor News
    • Government Policies
    • Hospital & Diagnostics
    • International Health News
    • MCI News
    • Medical Organization News
    • Medico Legal News
    • NBE News
    • NMC News
  • AYUSH
    • Ayurveda
      • Ayurveda Giuidelines
      • Ayurveda News
    • Homeopathy
      • Homeopathy Guidelines
      • Homeopathy News
    • Siddha
      • Siddha Guidelines
      • Siddha News
    • Unani
      • Unani Guidelines
      • Unani News
    • Yoga
      • Yoga Guidelines
      • Yoga News
  • State News
    • Andaman and Nicobar Islands
    • Andhra Pradesh
    • Arunachal Pradesh
    • Assam
    • Bihar
    • Chandigarh
    • Chattisgarh
    • Dadra and Nagar Haveli
    • Daman and Diu
    • Delhi
    • Goa
    • Gujarat
    • Haryana
    • Himachal Pradesh
    • Jammu & Kashmir
    • Jharkhand
    • Karnataka
    • Kerala
    • Ladakh
    • Lakshadweep
    • Madhya Pradesh
    • Maharashtra
    • Manipur
    • Meghalaya
    • Mizoram
    • Nagaland
    • Odisha
    • Puducherry
    • Punjab
    • Rajasthan
    • Sikkim
    • Tamil Nadu
    • Telangana
    • Tripura
    • Uttar Pradesh
    • Uttrakhand
    • West Bengal
  • Medical Education
    • Ayush Education News
    • Dentistry Education News
    • Medical Admission News
    • Medical Colleges News
    • Medical Courses News
    • Medical Universities News
    • Nursing education News
    • Paramedical Education News
    • Study Aborad
  • Industry
    • Health Investment News
    • Health Startup News
    • Medical Devices News
    • Pharma News
      • CDSCO (Central Drugs Standard Control Organisation) News
    • Pharmacy Education News
    • Industry Perspective
  • Home
  • Cardiology-CTVS
  • Cardiology & CTVS News
  • Ranolazine reduced...

Ranolazine reduced ventricular tachyarrhythmia burden among cardiac resynchronization therapy patients: RAID Trial

Medha BaranwalWritten by Medha Baranwal Published On 2022-05-23T09:15:23+05:30  |  Updated On 23 May 2022 6:50 AM GMT
Ranolazine reduced ventricular tachyarrhythmia burden among cardiac resynchronization therapy patients: RAID Trial

USA: Ranolazine is effective in reducing ventricular tachyarrhythmia (VTA) burden among high-risk patients without the concomitant use of antiarrhythmic drugs (AADs), without atrial fibrillation, and/or with cardiac resynchronization therapy-defibrillator (CRT-D) -- shows a recent study. Ranolazine addition however did not affect vta burden in patients already on AADs or those with AF. The...

USA: Ranolazine is effective in reducing ventricular tachyarrhythmia (VTA) burden among high-risk patients without the concomitant use of antiarrhythmic drugs (AADs), without atrial fibrillation, and/or with cardiac resynchronization therapy-defibrillator (CRT-D) -- shows a recent study. Ranolazine addition however did not affect vta burden in patients already on AADs or those with AF. The study appears in JACC: Clinical Electrophysiology.

Ranolazine treatment was shown to be associated with the reduction in recurrent ventricular tachycardia requiring suitable implantable cardioverter-defibrillator (ICD) therapy. Arwa Younis, Heart, Vascular and Thoracic Institute, Cleveland Clinic, Cleveland, Ohio, USA, and colleagues aimed to identify groups of patients in whom ranolazine treatment would result in the highest reduction of VTA burden.

For this purpose, the researchers performed Andersen-Gill analyses to identify variables associated with the risk of VTA burden among 1,012 patients enrolled in RAID. VTA burden defined as VTA episodes requiring appropriate treatment was the primary endpoint. 

The researchers reported the following findings:

  • Multivariate analysis identified 7 factors associated with increased VTA burden: history of VTA, age ≥65 years, New York Heart Association functional class ≥III, QRS complex (≥130 ms), low ejection fraction (<30%), atrial fibrillation (AF), and concomitant antiarrhythmic drug (AAD) therapy.
  • The effect of ranolazine on VTA burden was seen among patients without concomitant AAD therapy (HR [HR]: 0.68), whereas no effect was seen among those who are concomitantly treated with other AADs (HR: 1.33).
  • In patients with cardiac resynchronization therapy (CRT) ICDs, ranolazine treatment was associated with a 36% risk reduction for VTA recurrence (HR: 0.64), whereas among patients with ICDs without CRT no significant effect was noted (HR: 0.94).

Among high-risk HF patients implanted with defibrillators, predictors of increased ventricular tachyarrhythmia burden include a history of VTA, age ≥65 years, QRS duration (≥130 ms), NYHA functional class ≥III, AF, low LVEF (<30%), and the use of AADs. 

"Ranolazine treatment is effective in reducing the burden of ventricular tachyarrhythmia among cardiac resynchronization therapy patients, those without AF, or as single antiarrhythmic drugs (AADs) therapy," wrote the authors. In patients already on AADs, or AF patients, ranolazine addition does not result in a favorable effect on first or recurrent VTA."

Reference:

The study titled, "Reduction in Ventricular Tachyarrhythmia Burden in Patients Enrolled in the RAID Trial," appears in the journal JACC: Clinical Electrophysiology. 

DOI: 10.1016/j.jacep.2022.02.018

JACC ranolazine atrial fibrillation 
Source : JACC: Clinical Electrophysiology
Medha Baranwal
Medha Baranwal

    MSc. Biotechnology

    Medha Baranwal joined Medical Dialogues as an Editor in 2018 for Speciality Medical Dialogues. She covers several medical specialties including Cardiac Sciences, Dentistry, Diabetes and Endo, Diagnostics, ENT, Gastroenterology, Neurosciences, and Radiology. She has completed her Bachelors in Biomedical Sciences from DU and then pursued Masters in Biotechnology from Amity University. She has a working experience of 5 years in the field of medical research writing, scientific writing, content writing, and content management. She can be contacted at  editorial@medicaldialogues.in. Contact no. 011-43720751

    Show Full Article
    Next Story
    Similar Posts
    NO DATA FOUND

    Editorial

    Journal Club Today

    Health News Today

    © 2022 All Rights Reserved.
    Powered By: Hocalwire
    X
    X
    We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok